Superficial fungal infections in psoriatic patients treated with interleukin-17-related biological agents and their management
- VernacularTitle:白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略
- Author:
Xiaowen WANG
1
;
Ruoyu LI
Author Information
- Keywords: Psoriasis; Biological agents; Interleukin-17; Drug toxicity; Candidiasis, cutaneous
- From: Chinese Journal of Dermatology 2022;55(3):272-275
- CountryChina
- Language:Chinese
- Abstract: This review summarizes the contribution of interleukin-17 (IL-17) to the susceptibility to mucocutaneous fungal infections, and superficial fungal infections associated with IL-17-targeting biological agents, such as secukinumab, ixekizumab, brodalumab, bimekizumab and ustekinumab, in the treatment of psoriasis. The superficial fungal infections associated with the treatment with IL-17-related biological agents are usually mild or moderate, and most of them are limited, with a good response to anti-fungal therapy. In addition, this review introduces clinical evaluation, monitoring and treatment of related superficial fungal infections, and provides a basis for safe clinical use of IL-17-targeting biologics.
